Fig. 2: Wild-type IDH1 expression and clinical immunotherapy metrics in GBM patients. | Oncogene

Fig. 2: Wild-type IDH1 expression and clinical immunotherapy metrics in GBM patients.

From: Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1

Fig. 2

A IDH1, IDH1R132H, and control (GAPDH) protein expression in GL26 transfectants prior to implantation. B IDH1 transfection into GL26 prolongs C57BL/6 (B6) host survival after DC vaccine therapy. C Newly diagnosed GBM from 16 DC vaccine therapy patients were subjected to microarray expression analysis before and after treatment (n = 10), or genomic sequencing (n = 6), and stratified by retention and loss of IDH1/IDH2 expression or gene copies (copy number loss = CNL), respectively. IDH1 CNL tumors (n = 3) were excluded from IDH2 analysis, and IDH2 CNL tumors (n = 1) were excluded from IDH1 analyses. Patients retaining IDH1 but not IDH2 exhibited significantly longer overall survival. Survival differences between IDH1-loss and -retained groups was increased when GBM without post-treatment CD8 infiltration were excluded from analysis (n = 4 & 8, respectively; 372 vs. 716 days median; P = 0.006 by Log-Rank). D Post-vaccine IFNγ production by CD8 T cells, and CD8 signal within tumor tissue (Affymetrix HG-U133+2 probeset 205758_at), both failed to significantly correlate with patient survival.

Back to article page